Covid19 Clinical Trial - Anti COVID-19 Convalescent Plasma Therapy

Status Recruiting

Clinical Trial Summary

Why is the research needed? The pandemic known as COVID-19 is now spreading across the world with currently (April 10, 2020) more than 1 115 530 active cases and 96 791 deaths. In most affected countries the current goal is to 'flatten the curve' of the epidemic since there is no health care system that is able to treat an extremely high volume of patients all at once. There is a need for immediately applicable treatments for the patients at highest risk, which gains time until targeted therapies become available. A key feature in the pathomechanism of the disease is that the virus elicits an immunological over-reaction in the human body termed 'cytokine storm'. In susceptible patients this hyper-inflammation itself is a significant burden and may even inhibit the body to generate antibodies against the virus in adequate quantities. Therefore, identifying the subset of patients with excess cytokine response and supplementing them with convalescent plasma from recovered donors may be a life-saving treatment option. What is our study about? In light of recent promising data on plasma therapy in the treatment of COVID-19 and other viral epidemics, there is a need for better understanding the cytokine response to the virus in order to better characterize the target population for convalescent plasma therapy. Our hypothesis is that convalescent plasma transfusion from healthy donors who recovered from SARS CoV-2 is able to reduce the cytokine storm in addition to replenish the patient's own antibodies in the acutely infected phase of the disease. A plasmapheresis donation of 400ml will be performed in subjects who recovered from COVID-19 and who are otherwise eligible for plasma donation. The sample will be tested for anti-SARS CoV-2 neutralizing antibody titers and those that reach the level of 1:320 will be processed for transfusion at the Hungarian National Transfusion Service. Recipients will be COVID-19 patients requiring hospitalization regardless of the severity of the disease or other co-morbidities. A blood-type matched transfusion of 200 ml convalescent plasma will be infused in a single sitting through an iv. infusion of 4 hours. Recipients will be followed up at days 1, 3,7,12, 17, 28 for clinical symptoms, antibody levels and cytokine response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

COVID 19

Clinical Trial Details

NCT number	NCT04345679
Study type	Interventional
Source	Orthosera Kft.
Contact	Eszter Fodor, medical doctor
Phone	+36306640494
Email	eszter.fodor@orthosera.com
Status	Recruiting
Phase	Early Phase 1
Start date	April 14, 2020
Completion date	September 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04333732` - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION	Phase 3
Completed	`NCT04357457` - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia	Phase 3
Terminated	`NCT04435795` - Inhaled Ciclesonide for Outpatients With COVID19	Phase 2/Phase 3
Completed	`NCT04357444` - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	Phase 2
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT05052320` - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn	`NCT04426344` - Core Warming of COVID-19 Patients	N/A
Recruiting	`NCT05595031` - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Terminated	`NCT04401410` - Anti-SARS Cov-2 T Cell Infusions for COVID 19	Phase 1
Completed	`NCT04445337` - Stellate Ganglion Blockade in COVID-19 Positive Patients	N/A
Active, not recruiting	`NCT04374487` - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications	Phase 2
Completed	`NCT04403243` - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19	Phase 2
Completed	`NCT04375644` - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed	`NCT04394078` - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting	`NCT04407923` - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Withdrawn	`NCT04519411` - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure	N/A
Completed	`NCT04426305` - Community Health Workers Against COVID19	N/A
Recruiting	`NCT04492514` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation	Phase 2
Completed	`NCT04399980` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.